SANDERLING VENTURES MANAGEMENT V 4/A
4/A · ENDOCYTE INC · Filed Dec 12, 2012
Insider Transaction Report
Form 4/AAmended
ENDOCYTE INCECYT
SANDERLING VENTURES MANAGEMENT V
10% Owner
Transactions
- Purchase
Common Stock
2011-12-20$3.20/sh+1,589$5,085→ 32,355 total(indirect: By Sanderling Ventures Management VI) - Purchase
Common Stock
2011-12-21$3.16/sh+1,589$5,021→ 33,944 total(indirect: By Sanderling Ventures Management VI)
Holdings
- 149,003(indirect: By Sanderling Ventures Management V)
Common Stock
Footnotes (4)
- [F1]The form 4 is being amended to correct the number of shares acquired and the number of shares beneficially owned by the reporting persons following the acquisitions which was incorrectly reported in original filing.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.14 to $3.27, inclusive. The reporting person undertakes to provide Endocyte, Inc., any security holders of Endocyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Fred Middleton is the owner of Sanderling Ventures Management V and Sanderling Ventures Management VI Partnership and he may be deemed to have voting and investment power over shares held of record by Sanderling Ventures Management V and Sanderling Ventures Management VI Partnership. Mr. Middleton disclaims beneficial ownership of the shares directly held by the entities affiliated with Sanderling except to the extent of his individual pecuniary interest therein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.10 to $3.21, inclusive. The reporting person undertakes to provide Endocyte, Inc., any security holders of Endocyte, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.